At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Omega-3 Long Chain Polyunsaturated Fatty Acid (LCPUFA) Supplementation in Very Low Birth Weight Infants for The Prevention Retinopathy of Prematurity: Proposal for a Prospective Randomized Controlled Masked Clinical Trial With Lipidomic and Transcriptomic Analyses
In Brief
A Phase 2 clinical trial evaluating Omegaven and Standard lipids (primarily omega-6 fatty acids) for Retinopathy of Prematurity. Completed, enrolled 48 participants across 1 site.
Detailed Summary
Retinopathy of prematurity (ROP) is a blinding disease affecting infants born prematurely. These infants do not have enough essential fatty acids to structurally support the retina, the nerve tissue in the eye which allows us to see. A recent study showed that giving omega-3 (n-3) fatty acids to these infants soon after birth made them less likely to need invasive treatments for eye disease. This research trial will give young infants born prematurely n-3 fish oil treatment and look at how this changes factors in the blood that promote disease. Detailed blood studies comparing infants with and without ROP will be performed and the infants will be followed over time to assess their eye development.
Study Details
Timeline
Interventions
Infants will receive nutritional supplementation with omega-3 fatty acids (omegaven).
Infants will receive nutritional supplementation with standard intralipid, composed primarily of omega-6 fatty acids.